CLDX · NASDAQ
Celldex Therapeutics, Inc.
$28.08 -1.85 (-6.18%)
Company overview
Celldex Therapeutics, Inc., a biopharmaceutical company, develops therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics designed to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs include CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response found on dendritic cells, macrophages, and B cells, as well as on various cancer cells; and CDX-527, a bispecific antibody that uses the company's proprietary anti-PD-L1 and CD27 human antibodies to combine CD27 costimulation with PD-L1/PD-1 pathway blockade, helping to prime and activate anti-tumor T cell responses.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $2.2B
- Employees
- 186
- Headquarters
- Hampton, NJ
- Website
- celldex.com
- CEO
- Anthony S. Marucci
- Listed
- May 15, 1986
- P/E
- -6.58
- Dividend yield
- 0.00%
Company financials
- Revenue
- $820,000
- Gross profit
- -$34,000
- Operating income
- -$309M
- EBITDA
- -$300M
- Net income
- -$284M
- EPS
- -$4.27
- Total assets
- $511M
- Total debt
- $1.9M
- Gross margin
- -4.15%
- Net margin
- -34,596.22%
- Earnings yield
- -15.21%
No geographic segmentation.
Showing FY 2025
CLDX
1D
NASDAQ
O30.53H30.92L28.78C29.93+0.22 (+0.74%)Vol911.49K
News